Prostate News and Research

RSS

Nottingham scientists given green light to test new vaccine for malignant melanoma

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer.

27 May 2010

BioImagene launches digital pathology solutions suite in Europe

BioImagene, Inc., the leading provider of end-to-end digital pathology solutions, launched its suite of digital pathology solutions in Europe. The company will showcase these digital pathology solutions at the Woche der Pathologie Congress in Berlin, which takes place from May 27-30, 2010.

27 May 2010

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

As millions of Americans prepare to enjoy the great outdoors Memorial Day weekend, the National Council on Skin Cancer Prevention reminds everyone to practice sun-safe behaviors – pack those wide-brimmed hats in the suitcase. The incidence of melanoma (the most fatal of skin cancers) continues to rise significantly, at a rate faster than any of the seven most common cancers.

26 May 2010

Abstract submissions, registration now open for 2nd International Symposium on MR-guided Focused Ultrasound

Scheduled for October 17-20, 2010 at the Westfields Marriott near Dulles International Airport, Washington, DC, the symposium will be a premier event for scientists, clinicians and others interested in current and future applications of MR-guided focused ultrasound. The program will offer a multifaceted exploration of this emerging field and feature plenary sessions, panel discussions, poster presentations and technical exhibits.

26 May 2010

Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 30-36 month follow-up study of patients treated with NX-1207 in Study NX02-0016. The initial study, completed in the U.S. in 2007, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days and 6 months post-treatment with NX-1207 2.5 mg.

26 May 2010

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.

26 May 2010

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

A new way to deliver cancer-fighting drugs using tiny particles made from lipids and chemotherapy drugs may have the power to knock out malignancies with a one-two punch. The strategy holds promise for patients with many different kinds of cancers.

25 May 2010

REDUCE trial data published in the online version of European Urology

On 8 May an editorial about the Reduction by Dutasteride of Prostate Cancer Events trial by Fritz H. Schröder and Monique J. Roobol was published in the online version of European Urology, the scientific journal of the European Association of Urology.

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

Simbionix USA to launch two new hands-on training systems at AUA annual meeting

Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is launching two new hands-on training systems - the Lap Nepherctomy simulation module and the VirtaMed TURPSim. Both solutions will be revealed for the first time at the AUA annual meeting in San Francisco next week.

25 May 2010

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.

24 May 2010

Researchers study correlation between type 2 diabetes and increased risk of cancer

Cancer and diabetes - are risk factors the same for these two diseases? Or does diabetes cause processes in the body which promote the onset or growth of cancer? It is still unclear why diabetics have a higher rate of cancer than people who are not affected by this metabolic disorder.

21 May 2010

Data on serum DNA blood tests for early detection of cancer to be presented at ASCO 2010

Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Vitamin D plays much wider role in people's life

Vitamin D is the sunshine vitamin - we make it when our skin is exposed to UV rays. In a perfect world everyone would eat fresh, organic foods, get outside, and enjoy a little sunshine all year round. But with today's busy lifestyles and concerns about skin cancer many people are vitamin D deficient and don't know it.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

20 May 2010

British Columbians lead the way in battle against cancer

With some of the lowest death and incidence rates for cancers, British Columbia is leading Canada in the battle against cancer.

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

Prostate News and Research

Nottingham scientists given green light to test new vaccine for malignant melanoma

BioImagene launches digital pathology solutions suite in Europe

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

Abstract submissions, registration now open for 2nd International Symposium on MR-guided Focused Ultrasound

Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

REDUCE trial data published in the online version of European Urology

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Simbionix USA to launch two new hands-on training systems at AUA annual meeting

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Researchers study correlation between type 2 diabetes and increased risk of cancer

Data on serum DNA blood tests for early detection of cancer to be presented at ASCO 2010

Cancer Institute of New Jersey investigators target autophagy

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Vitamin D plays much wider role in people's life

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

British Columbians lead the way in battle against cancer

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News